Commonwealth Equity Services’s NovoCure NVCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-10,463
Closed -$179K 4153
2024
Q2
$179K Buy
+10,463
New +$184K ﹤0.01% 3672
2023
Q3
Sell
-8,401
Closed -$349K 3906
2023
Q2
$349K Buy
8,401
+866
+11% +$53.8K ﹤0.01% 2914
2023
Q1
$453 Sell
7,535
-210
-3% -$16.8K ﹤0.01% 2644
2022
Q4
$568K Buy
7,745
+799
+12% +$60.1K ﹤0.01% 2365
2022
Q3
$527K Sell
6,946
-728
-9% -$56.8K ﹤0.01% 2362
2022
Q2
$533K Sell
7,674
-664
-8% -$50K ﹤0.01% 2356
2022
Q1
$690K Sell
8,338
-229
-3% -$16.9K ﹤0.01% 2272
2021
Q4
$643K Buy
8,567
+2,985
+53% +$300K ﹤0.01% 2321
2021
Q3
$648K Sell
5,582
-159
-3% -$24K ﹤0.01% 2275
2021
Q2
$1.27M Buy
5,741
+362
+7% +$70.4K ﹤0.01% 1744
2021
Q1
$711K Sell
5,379
-2,121
-28% -$336K ﹤0.01% 2061
2020
Q4
$1.3M Buy
7,500
+269
+4% +$36.8K ﹤0.01% 1490
2020
Q3
$804K Sell
7,231
-54
-0.7% -$4.32K ﹤0.01% 1628
2020
Q2
$432K Buy
7,285
+2,644
+57% +$174K ﹤0.01% 1994
2020
Q1
$312K Sell
4,641
-295
-6% -$23.3K ﹤0.01% 2035
2019
Q4
$415K Buy
4,936
+1,674
+51% +$135K ﹤0.01% 2057
2019
Q3
$243K Buy
+3,262
New +$261K ﹤0.01% 2419
2016
Q1
Sell
-36,090
Closed -$807K 2246
2015
Q4
$807K Buy
+36,090
New +$862K 0.01% 1035

Other funds holding NVCR

Commonwealth Equity Services's NVCR Position: Q3 2024 in Review

Commonwealth Equity Services sold out of NovoCure (NVCR) in Q3 2024, closing a stake of 10,463 shares — an estimated $179K sold.

Commonwealth Equity Services first reported a position in NVCR in Q4 2015 and held it in 18 quarters. The position peaked at $1.3M in Q4 2020. 224 funds tracked by Wall St. Rank hold NVCR as of Q3 2024.

  • Commonwealth Equity Services reported no remaining NovoCure position as of Q3 2024 after selling out during the quarter.
  • Commonwealth Equity Services sold 10,463 NovoCure shares in Q3 2024, an estimated $179K.
  • Commonwealth Equity Services first reported a position in NovoCure in Q4 2015 and held it in 18 quarters.
  • Commonwealth Equity Services's NovoCure position peaked at $1.3M in Q4 2020.
  • 224 funds tracked by Wall St. Rank held NovoCure as of Q3 2024.

Based on Commonwealth Equity Services's 13F filing for Q3 2024, filed 18 Oct 2024.